GlassScriptPhysician profile
Johnasan M Gregory
NPI 1699774869
$534.62
in general payments reported to CMS, 2019-2025
12 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.68 · 2020: $11.94 · 2021: $39.47 · 2022: $58.46 · 2023: $17.16 · 2024: $167 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $130.22 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $92.75 | 2024-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.31 | 2019-2024 | Xifaxan |
| Aimmune Therapeutics, INC. | $53.22 | 2025 | Zenpep |
| Merz North America, INC. | $45.83 | 2022 | |
| Vivus LLC | $30.34 | 2024-2025 | Qsymia, Pancreaze |
| Boston Scientific Corporation | $24.93 | 2024 | Resolution 360 Clip |
| Lilly USA, LLC | $17.91 | 2025 | Omvoh |
| Pfizer INC. | $17.16 | 2023 | |
| Celltrion USA INC. | $16.24 | 2025 | Vegzelma |
| Celgene Corporation | $14.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.94 | 2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnasan Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.